Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. The company's proprietary enzyme rHuPH20 is used to facilitate the delivery of injected drugs and fluids, potentially reducing the treatment burden of other drugs and improving patient convenience and compliance. Halozyme's lead investigational drug candidate, PEGPH20, is a PEGylated recombinant human hyaluronidase under clinical development for the treatment of pancreatic cancer and other solid tumors. The company was founded in 1998 and is headquartered in San Diego, California.